Business Context and Reporting Period
This Form 8-K Current Report from IDEAYA Biosciences, Inc. (IDYA) was filed on July 9, 2024. The report provides preliminary financial estimates as of June 30, 2024, and details recent equity financing activities under an "at-the-market" (ATM) program.
Key Financial Metrics
- Cash and Liquidity: Approximately $952.7 million in cash, cash equivalents, and marketable securities as of June 30, 2024.
- Revenue and Profit: The filing does not provide specific revenue, profit, or margin figures for the period.
- Debt: No debt figures are disclosed in this report.
- Equity Financing: Between April 1, 2024, and July 5, 2024, the company sold 922,000 shares of common stock at a weighted average price of approximately $40.40 per share.
- ATM Facility Capacity: As of July 5, 2024, approximately $182.1 million remained available for sale under the $350.0 million ATM facility.
Material Changes and Preliminary Status
The financial data presented is preliminary and unaudited. The company has not yet completed its quarter-end financial close processes for the quarter ended June 30, 2024. Consequently, the reported cash balance is subject to change upon completion of financial statement closing procedures. No comparative data for prior periods is included in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: Management emphasizes that the preliminary data does not present all information necessary for a complete understanding of the company's financial condition. PricewaterhouseCoopers LLP has not audited or reviewed this data.
Contingencies: The reported cash position is an estimate based on information available as of July 9, 2024, and could be adjusted during the final close process.
Outlook: The company continues to utilize its ATM facility to raise capital, with significant capacity remaining.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and marketable securities balance in the upcoming Form 10-Q for the quarter ended June 30, 2024.
- Confirm the total proceeds generated from the ATM sales between April 1 and July 5, 2024, against the reported share count and weighted average price.
- Review the full Form 10-Q for revenue, operating expenses, and net loss figures, which are absent in this 8-K.
- Monitor future filings for updates on the remaining $182.1 million capacity under the ATM facility.